| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1002540664 |
| P356 | DOI | 10.1007/S40273-014-0173-7 |
| P698 | PubMed publication ID | 24906477 |
| P5875 | ResearchGate publication ID | 262929200 |
| P2093 | author name string | Erik Smets | |
| Josephine A Mauskopf | |||
| Anita J Brogan | |||
| Ines Adriaenssen | |||
| Sarah A L Manuel | |||
| P2860 | cites work | The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States | Q22242768 |
| Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 | ||
| Raltegravir with optimized background therapy for resistant HIV-1 infection | Q28288290 | ||
| The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy | Q33507274 | ||
| Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data | Q33585982 | ||
| Management of protease inhibitor-associated diarrhea | Q33943243 | ||
| Decline in the AIDS and death rates in the EuroSIDA study: an observational study | Q33967061 | ||
| CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study | Q34269641 | ||
| The direct costs of HIV/AIDS care | Q34497622 | ||
| The survival benefits of AIDS treatment in the United States | Q34533291 | ||
| Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count | Q34548243 | ||
| Risk factors for gastrointestinal adverse events in HIV treated and untreated patients | Q34605471 | ||
| Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial | Q34647153 | ||
| Maraviroc for previously treated patients with R5 HIV-1 infection | Q34806062 | ||
| A methodological review of models used to estimate the cost effectiveness of antiretroviral regimens for the treatment of HIV infection | Q35043404 | ||
| The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy | Q57181243 | ||
| Health care services utilization stratified by virological and immunological markers of HIV: evidence from a universal health care setting | Q57259631 | ||
| A Simple, Dynamic Measure of Antiretroviral Therapy Adherence Predicts Failure to Maintain HIV‐1 Suppression | Q57259691 | ||
| Modeling the Long-Term Outcomes and Costs of HIV Antiretroviral Therapy Using HIV RNA Levels: Application to a Clinical Trial | Q57847861 | ||
| Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the | Q58375437 | ||
| Predictors of optimal virological response to potent antiretroviral therapy | Q73064663 | ||
| Association between diarrhea and quality of life in HIV-infected patients receiving highly active antiretroviral therapy | Q79856800 | ||
| Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection | Q82533882 | ||
| Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature | Q35057790 | ||
| Cost-effectiveness analysis of initial HIV treatment under Italian guidelines | Q35602604 | ||
| The CD4 lymphocyte count and risk of clinical progression | Q37446757 | ||
| Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients | Q37604439 | ||
| Economic modeling of HIV treatments | Q37764266 | ||
| Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel | Q37773748 | ||
| Review article: the aetiology, investigation and management of diarrhoea in the HIV-positive patient. | Q37903384 | ||
| Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States. | Q38314922 | ||
| Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort | Q39669125 | ||
| European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. | Q40126108 | ||
| Estimating the proportion of patients infected with HIV who will die of comorbid diseases | Q40399268 | ||
| TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates | Q40417023 | ||
| Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. | Q40433154 | ||
| Effect of mycophenolate mofetil on immune response and plasma and lymphatic tissue viral load during and after interruption of highly active antiretroviral therapy for patients with chronic HIV infection: a randomized pilot study. | Q40542223 | ||
| Cost-minimization comparison of darunavir plus ritonavir and lopinavir/ritonavir in HIV-1 infected treatment-naïve women of childbearing age. | Q42248314 | ||
| Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis | Q42623275 | ||
| US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial | Q42772433 | ||
| Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA. | Q42772440 | ||
| Provincial squeeze on generic prices continues | Q42918383 | ||
| Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials | Q43285218 | ||
| Cost of medical care for HIV-infected patients within a regional population from 1997 to 2006. | Q43545552 | ||
| The lifetime cost of treating a person with HIV. | Q43838666 | ||
| Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia | Q43864142 | ||
| Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. | Q44043469 | ||
| Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy | Q44300131 | ||
| Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection | Q44509935 | ||
| Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures | Q44561806 | ||
| Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States. | Q45055651 | ||
| Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen | Q45272010 | ||
| Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. | Q45937663 | ||
| Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels | Q46052818 | ||
| Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study | Q46121151 | ||
| Adherence to combined Lamivudine + Zidovudine versus individual components: a community-based retrospective medicaid claims analysis | Q46233887 | ||
| Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States | Q46407326 | ||
| Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease | Q46455671 | ||
| Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection | Q46466415 | ||
| Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy | Q46480923 | ||
| Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. | Q46492574 | ||
| All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration | Q47918470 | ||
| Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs | Q50176584 | ||
| The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences. | Q50660038 | ||
| Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. | Q51910874 | ||
| Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. | Q51910877 | ||
| Twenty years of therapy for HIV-1 infection. | Q53382316 | ||
| ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults. | Q55000342 | ||
| Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes | Q56533400 | ||
| Estudio longitudinal de adherencia, satisfacción y efectividad del tratamiento antirretroviral administrado una vez al día, frente a dos veces al día, en una cohorte española de infectados por el VIH (estudio CUVA: cualquiera una vez al día) | Q56794465 | ||
| Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study | Q57075689 | ||
| P433 | issue | 9 | |
| P921 | main subject | ritonavir | Q422618 |
| P304 | page(s) | 903-917 | |
| P577 | publication date | 2014-09-01 | |
| P1433 | published in | PharmacoEconomics | Q7180778 |
| P1476 | title | Cost effectiveness of darunavir/ritonavir combination antiretroviral therapy for treatment-naive adults with HIV-1 infection in Canada | |
| P478 | volume | 32 |
| Q40215329 | Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical tri |
| Q36102240 | Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study |
Search more.